Vincristine

Generic Name: Vincristine

Brand Names: Marqibo, Vincasar

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₅₆N_₄O_₁₀

CAS Number: 57-22-7

Unique Ingredient Identifier: 5J49Q6B70F

Background: Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Indication: Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma
Hepatosplenic T-cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Peripheral T-cell Lymphoma

Interventions: Drug: prednisone
Drug: cyclophosphamide
Drug: etoposide
Drug: Vincristine
Drug: pralatrexate
Other: laboratory biomarker analysis
Genetic: comparative genomic hybridization
Genetic: gene expression analysis
Genetic: nucleic acid sequencing
Genetic: mutation analysis
Other: immunohistochemistry staining method
Genetic: microarray analysis
Genetic: RNA analysis

First Posted Date: 2011-04-18

Last Posted Date: 2023-09-22

Lead Sponsor: University of Nebraska

Target Recruit Count: 34

Registration Number: NCT01336933

Locations: 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 6 locations

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Phase 3

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Obinutuzumab
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2011-04-11

Last Posted Date: 2022-08-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1401

Registration Number: NCT01332968

Locations: 🇨🇦
North York General Hospital, Toronto, Ontario, Canada
🇦🇺
St Vincent'S Hospital; Haematology, Fitzroy, Victoria, Australia
🇨🇦
Humber River Hospital, Toronto, Ontario, Canada

and more 180 locations

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Metformin
Drug: Vincristine
Drug: Dexamethasone
Drug: PEG-asparaginase
Drug: Doxorubicin
Drug: Intrathecal chemotherapy

First Posted Date: 2011-03-28

Last Posted Date: 2017-08-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 14

Registration Number: NCT01324180

Locations: 🇺🇸
Holtz Children's Hospital University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
Arnold Palmer Hospital for Children, Orlando, Florida, United States
🇺🇸
All Children's Hospital, Saint Petersburg, Florida, United States

and more 2 locations

Stage I/II Nasal NK Cell Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Radiation: Radiation
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2011-03-23

Last Posted Date: 2015-02-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01321008

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Phase 2

Terminated

Conditions: Bone Cancer
Ewing's Sarcoma

Interventions: Drug: Irinotecan
Drug: Vincristine
Drug: Temozolomide
Drug: Doxorubicin
Drug: Cytoxan
Drug: Pegfilgrastim

First Posted Date: 2011-03-14

Last Posted Date: 2017-11-24

Lead Sponsor: Stanford University

Target Recruit Count: 3

Registration Number: NCT01313884

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Phase 1

Completed

Conditions: Lymphoma, Large-Cell, Anaplastic
Lymphoma, NK-cell
Lymphoma, T-cell

Interventions: Drug: brentuximab vedotin
Drug: cyclophosphamide
Drug: prednisone
Drug: doxorubicin
Drug: vincristine

First Posted Date: 2011-03-07

Last Posted Date: 2017-06-28

Lead Sponsor: Seagen Inc.

Target Recruit Count: 39

Registration Number: NCT01309789

Locations: 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford Cancer Center, Stanford, California, United States

and more 8 locations

A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients

Phase 3

Conditions: Follicular Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Vincristine
Drug: Prednisolone

First Posted Date: 2011-02-25

Last Posted Date: 2011-05-06

Lead Sponsor: University of Liverpool

Target Recruit Count: 680

Registration Number: NCT01303887

Locations: 🇬🇧
Queen's Hospital, Burton, Burton-upon-Trent, United Kingdom
🇬🇧
Princess Royal Hospital, Bromley, Hayes, United Kingdom
🇬🇧
Trafford General Hospital, Davyhulme, United Kingdom

and more 70 locations

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Phase 3

Terminated

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Obinutuzumab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2011-02-01

Last Posted Date: 2019-04-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1418

Registration Number: NCT01287741

Locations: 🇨🇦
Humber River Hospital, Toronto, Ontario, Canada
🇺🇸
UCLA - School of Medicine; Division of Hematology/Oncology, Los Angeles, California, United States
🇵🇱
Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk, Poland

and more 232 locations